Search
Returning search results with filters:
Remove filter for
Issue: Health products
Remove filter for
Last updated: 2022
Remove filter for
Type: Alert
Clear all
Search filters
Type
Audience
Category
Issue
Last updated
- (-) 2022
- December 20222 results available
- November 20224 results available
- October 20224 results available
- September 20226 results available
- August 20228 results available
- July 20224 results available
- June 20224 results available
- May 20222 results available
- April 20224 results available
- March 20225 results available
- February 20224 results available
- January 20225 results available
Displaying 46 - 52 of 52 items.
BEOVU (brolucizumab) – Risk of Intraocular Inflammation, Retinal Vasculitis and/or Retinal Vascular Occlusion
AlertHealth professional risk communication | 2022-02-03
Health Canada warns that products sold by Kerela Ayurvedic & Natural Herbal Consultation in Toronto, ON, may pose serious health risks
AlertPublic advisory | 2022-02-01
PAXLOVID (nirmatrelvir and ritonavir) - Dosing and Dispensing in Renal Impairment, Risk of Serious Adverse Reactions Due to Drug Interactions, and English-Only Labels
AlertHealth professional risk communication | 2022-01-17
XELJANZ/XELJANZ XR (tofacitinib) – Risk of Major Adverse Cardiovascular Events, Malignancy, Thrombosis and Infection
AlertHealth professional risk communication | 2022-01-12
Shelf Life Extension for the SPIKEVAX (elasomeran) COVID-19 Vaccine with Printed Expiry Dates on Vial and Carton Labels
AlertHealth professional risk communication | 2022-01-11
Casirivimab and Imdevimab – High Risk of Treatment Failure Due to Circulation of SARS-CoV-2 Omicron Variant
AlertHealth professional risk communication | 2022-01-07